Open AccessSafety and Tolerability of Cariprazine in Patients with Schizophrenia: A Pooled Analysis of Eight Phase II/III Studies
Author(s) -
Christoph Born,
B. Sebe,
K. Acsai,
István Laszlovszky,
B. Szatmári,
Willie Earley,
György Németh
Publication year - 2021
Publication title -
neuropsychiatric disease and treatment
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.819
H-Index - 67
eISSN - 1178-2021
pISSN - 1176-6328
DOI - 10.2147/ndt.s301225
Subject(s) - akathisia , medicine , discontinuation , tolerability , extrapyramidal symptoms , adverse effect , antipsychotic , bipolar i disorder , schizophrenia (object oriented programming) , population , psychiatry , bipolar disorder , mania , environmental health , lithium (medication)
Long-term treatment with antipsychotic agents is indicated for patients with schizophrenia, but treatment is associated with adverse events (AEs) that contribute to medication discontinuation and nonadherence. Understanding drug safety profiles is critical to avoid unwanted side effects. Cariprazine is a potent dopamine D 3 /D 2 receptor partial agonist that is approved for the treatment of adults with schizophrenia (EU, US) and acute manic/mixed and depressive episodes associated with bipolar I disorder (US).